Infective endocarditis (IE) is an infection of the inner lining of the heart chambers and valves caused by bacteria, fungi, or other microbial organisms that enter the bloodstream and adhere to cardiac structures. IE can develop acutely or gradually depending on the causative organism and the presence of underlying cardiac conditions, and may lead to serious cardiac damage and systemic complications. Documented disease subtypes include subacute bacterial endocarditis, bacterial endocarditis, and mycotic endocarditis. Precise prevalence estimates for infective endocarditis are not well established in the structured data available for this condition.

Clinical signs and symptoms of infective endocarditis are variable. As described in the disease definition, fever and flu-like manifestations are common presentations. The condition can cause cardiac damage and complications in organ systems beyond the heart; no structured phenotype data are included in the knowledge packet for this condition.

Infective endocarditis results from microbial infection rather than inherited genetic mechanisms. No causative genes or inheritance patterns are identified in this knowledge packet, consistent with the acquired infectious nature of the condition. The disease arises when bacteria, fungi, or other microorganisms colonize the bloodstream and adhere to cardiac valvular or mural surfaces, as described in the disease definition.

No structured diagnostic criteria are provided in the knowledge packet for this condition. The disease definition characterizes infective endocarditis by its clinical course, causative organisms, and variable pace of onset.

Three FDA-approved antibiotic agents for infective endocarditis are identified in this knowledge packet: ceftobiprole medocaril sodium (ZEVTERA), approved by the FDA in April 2024; vancomycin hydrochloride (VANCOMYCIN HYDROCHLORIDE); and vancomycin (TYZAVAN), approved in 2019. All three are small-molecule antibacterial agents approved through FDA's Center for Drug Evaluation and Research. Calpurbatug carries an orphan drug designation for infective endocarditis but is not an approved therapy. The disease definition notes that surgical intervention to repair or replace cardiac valves may be required in some cases.

Structured prognosis data are not provided in the knowledge packet for this condition. The disease definition describes infective endocarditis as capable of causing serious and sometimes fatal complications, with clinical course varying depending on the causative organism and underlying cardiac conditions.

Numerous active clinical trial records are certified for infective endocarditis on ClinicalTrials.gov. Active studies include a Phase 3 trial comparing antibiotic regimens for prosthetic valve endocarditis (NCT07345325), a risk-reduction interventional study (NCT05721781), and an observational registry (NCT06434012). Active clinical trials for this condition are listed on ClinicalTrials.gov.